Akorn Faces Hurdles In Returning To Path Of Profitable Growth
Executive Summary
A new management team at Akorn is making progress on moving on from Fresenius Kabi’s ill-fated takeover bid; but putting manufacturing problems behind the US injectables and ophthalmics specialist is proving difficult.
You may also be interested in...
Akorn Extends Lenders Standstill With Aim To Sell Company
US generics company Akorn, which has been struggling since Germany’s Fresenius walked away from a $4.3bn merger three years ago, plans to put itself up for sale under an extended standstill agreement with lenders.
Akorn Reports ‘Sustained’ Progress On FDA Issues
Beleaguered niche generic drugmaker Akorn has reported stronger-than-expected first-quarter earnings and says it is making progress on resolving FDA-related compliance problems.